Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C.

Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.

2.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
3.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.

PMID:
20220773
4.

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.

5.

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C.

Int J Cancer. 2009 Aug 15;125(4):879-86. doi: 10.1002/ijc.24461.

6.

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M, Rossig C.

Cancer Immunol Immunother. 2009 Dec;58(12):1991-2001. doi: 10.1007/s00262-009-0704-9. Epub 2009 Apr 10.

PMID:
19360406
7.

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, Bollard CM, Moosmann A, Bisping G, Rossig C.

J Immunother. 2009 Apr;32(3):310-21. doi: 10.1097/CJI.0b013e31819b7c30.

8.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

Landmeier S, Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, Juergens H, Rossig C.

Cancer Res. 2007 Sep 1;67(17):8335-43.

9.

CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C.

Clin Exp Immunol. 2006 Jun;144(3):447-57.

10.

Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor.

Gattenlöhner S, Marx A, Markfort B, Pscherer S, Landmeier S, Juergens H, Müller-Hermelink HK, Matthews I, Beeson D, Vincent A, Rossig C.

Cancer Res. 2006 Jan 1;66(1):24-8.

11.

Adoptive cellular immunotherapy with CD19-specific T cells.

Rössig C, Pscherer S, Landmeier S, Altvater B, Jürgens H, Vormoor J.

Klin Padiatr. 2005 Nov-Dec;217(6):351-6.

PMID:
16307422

Supplemental Content

Loading ...
Support Center